(Reuters) -Eli Lilly said on Tuesday it will invest $5 billion to build a manufacturing facility in Virginia, the first of four new U.S. plants the drugmaker has planned as it moves to expand domestic production and hedge against potential tariffs.

Global pharmaceutical companies have been increasing U.S. investment to bolster manufacturing capacity after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.

Trump has said he would start with small pharma tariffs and could raise them to as high as 250% to boost U.S. production.

Earlier this year, Lilly outlined plans to spend at least $27 billion on four new U.S. manufacturing sites to counter potential drug import duties. Since 2020, the company has

See Full Page